WO2023145898A1 - 慢性腎臓病の尿検査方法 - Google Patents

慢性腎臓病の尿検査方法 Download PDF

Info

Publication number
WO2023145898A1
WO2023145898A1 PCT/JP2023/002703 JP2023002703W WO2023145898A1 WO 2023145898 A1 WO2023145898 A1 WO 2023145898A1 JP 2023002703 W JP2023002703 W JP 2023002703W WO 2023145898 A1 WO2023145898 A1 WO 2023145898A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
kidney disease
urine
chronic kidney
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2023/002703
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
格 山本
憲吾 柳田
恵子 山本
智啓 吉川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Niigata University NUC
Tosoh Corp
Original Assignee
Niigata University NUC
Tosoh Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Niigata University NUC, Tosoh Corp filed Critical Niigata University NUC
Priority to JP2023577040A priority Critical patent/JPWO2023145898A1/ja
Publication of WO2023145898A1 publication Critical patent/WO2023145898A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/493—Physical analysis of biological material of liquid biological material urine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Definitions

  • the present invention relates to a urine test method for chronic kidney disease and a drug for performing the urine test.
  • the present invention also relates to chronic kidney disease markers.
  • Chronic kidney disease refers to a state in which findings suggestive of decreased renal function or renal failure expressed by glomerular filtration rate (GFR) persists chronically (3 months or more), especially diabetes is a factor The disease is called Diabetic Kidney Disease (DKD).
  • DKD Diabetic Kidney Disease
  • There is no effective treatment for chronic kidney disease and if chronic kidney disease progresses and renal function decline progresses, there is a risk of end-stage renal failure (uremia), necessitating dialysis or kidney transplantation.
  • uremia end-stage renal failure
  • the number of dialysis patients due to renal failure has exceeded 2.1 million worldwide and is expected to increase exponentially in the future.
  • chronic kidney disease can usually be classified into stages 1 to 5 according to the degree of progression, using GFR as an index. However, it is possible to detect conditions prior to the condition in which microalbuminuria in urine is detected).
  • At least one type of protein is detected as a urinary marker for renal damage, but from the viewpoint of increasing the accuracy of testing for chronic kidney disease, the amount of multiple types of protein is detected.
  • at least one protein selected from the group consisting of AMBP, ZAG and PLG is preferred, and AMBP is more preferred, from the viewpoint of relatively high urinary concentration.
  • SPR method surface plasmon resonance method
  • a capturing antibody By immobilizing a capturing antibody on a sensor chip (GLM) and then contacting the target protein in a urine sample, the target protein recognized by the antibody is captured.
  • LLM sensor chip
  • This quantification method utilizes the fact that the change in this angle (resonance unit, RU) is proportional to the amount of bound protein.
  • Medical intervention and treatment for such chronic kidney disease is not particularly limited, but guidance for blood sugar level management, lifestyle improvement, dietary guidance, blood pressure management, anemia management, electrolyte management, uremic toxin management, immune management, and lipid management or medication.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PCT/JP2023/002703 2022-01-27 2023-01-27 慢性腎臓病の尿検査方法 Ceased WO2023145898A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023577040A JPWO2023145898A1 (https=) 2022-01-27 2023-01-27

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022011271 2022-01-27
JP2022-011271 2022-01-27

Publications (1)

Publication Number Publication Date
WO2023145898A1 true WO2023145898A1 (ja) 2023-08-03

Family

ID=87471689

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2023/002703 Ceased WO2023145898A1 (ja) 2022-01-27 2023-01-27 慢性腎臓病の尿検査方法

Country Status (2)

Country Link
JP (1) JPWO2023145898A1 (https=)
WO (1) WO2023145898A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025192605A1 (ja) * 2024-03-12 2025-09-18 株式会社GALTS Pharma 慢性腎臓病の治療薬、及び慢性腎臓病の治療薬のスクリーニング法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170153249A1 (en) * 2014-07-01 2017-06-01 Bio-Rad Innovations Early prediction markers of diabetic nephropathy
JP2019502902A (ja) * 2015-11-18 2019-01-31 ジェンザイム・コーポレーション 多発性嚢胞腎のバイオマーカーおよびその使用
WO2021152371A1 (en) * 2020-01-31 2021-08-05 Warszawski Uniwersytet Medyczny Method of differentiating of a chronic kidney disease or glomerulopathy, method of monitoring a response to treatment of a chronic kidney disease or glomerulopathy in a subject and a method of treatment of a chronic kidney disease or glomerulopathy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170153249A1 (en) * 2014-07-01 2017-06-01 Bio-Rad Innovations Early prediction markers of diabetic nephropathy
JP2019502902A (ja) * 2015-11-18 2019-01-31 ジェンザイム・コーポレーション 多発性嚢胞腎のバイオマーカーおよびその使用
WO2021152371A1 (en) * 2020-01-31 2021-08-05 Warszawski Uniwersytet Medyczny Method of differentiating of a chronic kidney disease or glomerulopathy, method of monitoring a response to treatment of a chronic kidney disease or glomerulopathy in a subject and a method of treatment of a chronic kidney disease or glomerulopathy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GOOD DAVID M., ZÜRBIG PETRA, ARGILÉS ÀNGEL, BAUER HARTWIG W., BEHRENS GEORG, COON JOSHUA J., DAKNA MOHAMMED, DECRAMER STÉPHANE, DE: "Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease", MOLECULAR & CELLULAR PROTEOMICS, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 9, no. 11, 1 November 2010 (2010-11-01), US , pages 2424 - 2437, XP093082428, ISSN: 1535-9476, DOI: 10.1074/mcp.M110.001917 *
GUANJIE FAN;TONGQING GONG;YUPING LIN;JIANPING WANG;LU SUN;HUA WEI;XING YANG;ZHENJIE LIU;XINLIANG LI;LING ZHAO;LAN SONG;JIALI HE;HA: "Urine proteomics identifies biomarkers for diabetic kidney disease at different stages", CLINICAL PROTEOMICS, SPRINGER, US, vol. 18, no. 1, 29 December 2021 (2021-12-29), US , pages 1 - 12, XP021300626, ISSN: 1542-6416, DOI: 10.1186/s12014-021-09338-6 *
SIWY JUSTYNA, ZÜRBIG PETRA, ARGILES ANGEL, BEIGE JOACHIM, HAUBITZ MARION, JANKOWSKI JOACHIM, JULIAN BRUCE A., LINDE PETER G., MARX: "Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis", NEPHROLOGY DIALYSIS TRANSPLANTATION, OXFORD UNIVERSITY PRESS, GB, GB , pages 2079 - 2089, XP093082427, ISSN: 0931-0509, DOI: 10.1093/ndt/gfw337 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025192605A1 (ja) * 2024-03-12 2025-09-18 株式会社GALTS Pharma 慢性腎臓病の治療薬、及び慢性腎臓病の治療薬のスクリーニング法

Also Published As

Publication number Publication date
JPWO2023145898A1 (https=) 2023-08-03

Similar Documents

Publication Publication Date Title
JP5960717B2 (ja) 自閉症の診断、治療におけるバイオマーカーおよびその使用
Naguib et al. Serum level of the autophagy biomarker Beclin-1 in patients with diabetic kidney disease
JP2014506244A6 (ja) 自閉症の診断、治療におけるバイオマーカーおよびその使用
CA2798713A1 (en) Markers for acute kidney injury
EP3811083B1 (en) Protein biomarkers for nephropathy and applications thereof
Tong et al. Identification of salivary peptidomic biomarkers in chronic kidney disease patients undergoing haemodialysis
JP2025143471A (ja) 腎病態の評価を補助する方法、腎病態の評価システム及び腎病態の評価プログラム
CN112236678A (zh) 用于多发伤患者的创伤相关并发症预后的pro-adm
WO2023145898A1 (ja) 慢性腎臓病の尿検査方法
Hur et al. Role of plasma presepsin, procalcitonin and C-reactive protein levels in determining the severity and mortality of community-acquired pneumonia in the emergency department
CN108896771B (zh) Guca2a蛋白在骨关节炎中的用途
WO2011063389A2 (en) Normalization of platelet biomarkers
CN117517679A (zh) 载脂蛋白h作为生物标志物在诊断、预测或监测儿童脓毒症的进展中的应用
EP4549941A1 (en) Colorectal cancer biomarker and use thereof
JP7633481B2 (ja) 薬剤性間質性肺炎の代謝物診断バイオマーカー
BR112020004138A2 (pt) pro-adm como marcador de monitoramento terapêutico para pacientes doentes em estado crítico
KR102314642B1 (ko) 파브리 병 진단용 바이오 마커 및 이의 용도
WO2019242751A1 (en) Small molecular biomarkers for nephropathy and applications thereof
JPWO2020080482A1 (ja) 血液中のシスタチンｃ量に基づく腎機能検査結果の妥当性を検定する方法
WO2020080491A1 (ja) 血液中のクレアチニン量に基づく腎機能検査結果の妥当性を検定する方法
TW202028746A (zh) 用以判定關鍵期之腎損傷之標記
TW202107085A (zh) 用以判定關鍵期之腎損傷之標記
US20240110916A1 (en) Method for treating hepatocellular carcinoma
JP7300642B2 (ja) 特発性肺線維症の予後予測方法
JP2024113271A (ja) 癌の腫瘍マーカー

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23747108

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2023577040

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23747108

Country of ref document: EP

Kind code of ref document: A1